Show Summary Details
Page of

Palliation of nausea and vomiting 

Palliation of nausea and vomiting
Chapter:
Palliation of nausea and vomiting
Author(s):

Janet R. Hardy

, Paul Glare

, Patsy Yates

, and Kathryn A. Mannix

DOI:
10.1093/med/9780199656097.003.0202
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 May 2021

Nausea and vomiting (NV) are unpleasant symptoms reported as highly distressing by sufferers and have a significant impact on activities of daily living. The prevalence of nausea is 6-68% in people with advanced cancer, 17-48% in heart disease, 30-43% in renal disease, and 43-49% in people with AIDS and is not always associated with vomiting. Several multifactorial clinical syndromes can contribute to NV in patients with advanced illness. Two strategies have been proposed for the management of nausea and vomiting: the mechanistic and the empirical approach. Most of the evidence supporting the use of antiemetic drugs in palliative care has been extrapolated from trials of chemotherapy- and radiotherapy-induced NV. An ideal measurement tool for the assessment of NV and retching has yet to be developed. Inherent in the management of NV is to maximize treatment of those symptoms commonly associated with NV.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.